Cocrystal Pharma Inc (COCP)vsVertex Pharmaceuticals Inc (VRTX)
COCP
Cocrystal Pharma Inc
$1.24
+0.81%
HEALTHCARE · Cap: $23.89M
VRTX
Vertex Pharmaceuticals Inc
$519.51
+0.79%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 3814203% more annual revenue ($12.59B vs $330,000). VRTX leads profitability with a 35.0% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
COCP
Avoid21
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.7%
Fair Value
$2.37
Current Price
$1.24
$1.13 discount
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$519.51
$443.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 26.9% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Trading at 15.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : COCP
The strongest argument for COCP centers on Revenue Growth. Revenue growth of 26.9% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : COCP
The primary concerns for COCP are Price/Book, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
COCP profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
COCP carries more volatility with a beta of 1.48 — expect wider price swings.
COCP is growing revenue faster at 26.9% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 21/100), backed by strong 35.0% margins and 12.5% revenue growth. COCP offers better value entry with a 59.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cocrystal Pharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic viral diseases. The company is headquartered in Bothell, Washington.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?